HDACs and HDAC Inhibitors in Cancer Development and Therapy
- PMID: 27599530
- PMCID: PMC5046688
- DOI: 10.1101/cshperspect.a026831
HDACs and HDAC Inhibitors in Cancer Development and Therapy
Abstract
Over the last several decades, it has become clear that epigenetic abnormalities may be one of the hallmarks of cancer. Posttranslational modifications of histones, for example, may play a crucial role in cancer development and progression by modulating gene transcription, chromatin remodeling, and nuclear architecture. Histone acetylation, a well-studied posttranslational histone modification, is controlled by the opposing activities of histone acetyltransferases (HATs) and histone deacetylases (HDACs). By removing acetyl groups, HDACs reverse chromatin acetylation and alter transcription of oncogenes and tumor suppressor genes. In addition, HDACs deacetylate numerous nonhistone cellular substrates that govern a wide array of biological processes including cancer initiation and progression. This review will discuss the role of HDACs in cancer and the therapeutic potential of HDAC inhibitors (HDACi) as emerging drugs in cancer treatment.
Copyright © 2016 Cold Spring Harbor Laboratory Press; all rights reserved.
Figures
Similar articles
-
Using Histone Deacetylase Inhibitors to Analyze the Relevance of HDACs for Translation.Methods Mol Biol. 2017;1510:77-91. doi: 10.1007/978-1-4939-6527-4_6. Methods Mol Biol. 2017. PMID: 27761814
-
Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy.Life Sci. 2021 Jul 15;277:119504. doi: 10.1016/j.lfs.2021.119504. Epub 2021 Apr 16. Life Sci. 2021. PMID: 33872660 Review.
-
The role of histone deacetylases (HDACs) in human cancer.Mol Oncol. 2007 Jun;1(1):19-25. doi: 10.1016/j.molonc.2007.01.001. Epub 2007 Mar 7. Mol Oncol. 2007. PMID: 19383284 Free PMC article. Review.
-
Deacetylation of nonhistone proteins by HDACs and the implications in cancer.Handb Exp Pharmacol. 2011;206:39-56. doi: 10.1007/978-3-642-21631-2_3. Handb Exp Pharmacol. 2011. PMID: 21879445 Review.
-
Histone Deacetylase Inhibitors Modulating Non-epigenetic Players: The Novel Mechanism for Small Molecule Based Therapeutic Intervention.Curr Drug Targets. 2018;19(6):593-601. doi: 10.2174/1389450117666160527143257. Curr Drug Targets. 2018. PMID: 27231104 Review.
Cited by
-
Chidamide induces apoptosis in DLBCL cells by suppressing the HDACs/STAT3/Bcl‑2 pathway.Mol Med Rep. 2021 May;23(5):308. doi: 10.3892/mmr.2021.11947. Epub 2021 Mar 2. Mol Med Rep. 2021. PMID: 33649847 Free PMC article.
-
LINC00518: a key player in tumor progression and clinical outcomes.Front Immunol. 2024 Jul 23;15:1419576. doi: 10.3389/fimmu.2024.1419576. eCollection 2024. Front Immunol. 2024. PMID: 39108268 Free PMC article. Review.
-
Epigenetic Dysregulation and Its Correlation with the Steroidogenic Machinery Impacting Breast Pathogenesis: Data Mining and Molecular Insights into Therapeutics.Int J Mol Sci. 2023 Nov 18;24(22):16488. doi: 10.3390/ijms242216488. Int J Mol Sci. 2023. PMID: 38003678 Free PMC article.
-
Histone Deacetylases in Retinoblastoma.Int J Mol Sci. 2024 Jun 24;25(13):6910. doi: 10.3390/ijms25136910. Int J Mol Sci. 2024. PMID: 39000021 Free PMC article. Review.
-
Nanotechnology-Based Histone Deacetylase Inhibitors for Cancer Therapy.Front Cell Dev Biol. 2020 Jun 3;8:400. doi: 10.3389/fcell.2020.00400. eCollection 2020. Front Cell Dev Biol. 2020. PMID: 32582697 Free PMC article. Review.
References
-
- Adams H, Fritzsche FR, Dirnhofer S, Kristiansen G, Tzankov A. 2010. Class I histone deacetylases 1, 2 and 3 are highly expressed in classical Hodgkin's lymphoma. Expert Opin Ther Targets 14: 577–584. - PubMed
-
- Aghdassi A, Sendler M, Guenther A, Mayerle J, Behn CO, Heidecke CD, Friess H, Buchler M, Evert M, Lerch MM, et al. 2012. Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer. Gut 61: 439–448. - PubMed
-
- Ahn MY, Ahn JW, Kim HS, Lee J, Yoon JH. 2015. Apicidin inhibits cell growth by downregulating IGF-1R in salivary mucoepidermoid carcinoma cells. Oncol Rep 33: 1899–1907. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources